Cargando…

Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)

Introduction Clinical guidelines recommend anticoagulation therapy for the treatment of cancer-associated venous thromboembolism (VTE), but little is known about preferences. Therefore, the objective of this discrete choice experiment (DCE) was to elucidate patient preferences regarding anticoagula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Picker, Nils, Lee, Agnes Y., Cohen, Alexander T., Maraveyas, Anthony, Beyer-Westendorf, Jan, Mantovani, Lorenzo G., Abdelgawwad, Khaled, Fatoba, Samuel, Thate-Waschke, Inga-Marion, Bach, Miriam, Wilke, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850882/ https://www.ncbi.nlm.nih.gov/pubmed/32877956 http://dx.doi.org/10.1055/s-0040-1714739

Ejemplares similares

Cancer‐Associated ThrOmboSIs – Patient‐Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes
por: Maraveyas, Anthony, et al.
Publicado: (2021)

COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study
por: Cohen, Alexander T., et al.
Publicado: (2018)

How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians’ Preferences
por: Müller, Sabrina, et al.
Publicado: (2020)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

The Public Libary of Renaissance Florence. Niccolò Niccoli, Cosimo de Medici and the Library of San Marco
Publicado: (1977)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Inflammatory Bowel Disease Patients’ Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study
por: Schubert, Stefan, et al.
Publicado: (2022)

Reproductive issues in women on direct oral anticoagulants
por: Beyer‐Westendorf, Jan, et al.
Publicado: (2021)

Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment
por: Haac, Bryce E, et al.
Publicado: (2017)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Betrixaban for prevention of venous thromboembolism in acute medically ill patients
por: Beyer-Westendorf, Jan, et al.
Publicado: (2018)

Correction: Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment
Publicado: (2017)

Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Isolated pancreatic heamorrhage in association with anticoagulation
por: Chiu, Keith, et al.
Publicado: (2013)

The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study
por: Sheard, Laura, et al.
Publicado: (2012)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Preferences of Patients with Chronic Hepatitis B – A Discrete Choice Experiment on the Acceptability of Functional Cure
por: Hardtstock, Fraence, et al.
Publicado: (2020)

Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment
por: Zhao, Jiaxi, et al.
Publicado: (2021)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Thromboembolism and anticoagulation after Fontan surgery
por: Viswanathan, Sangeetha
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS
por: Brückner, Lea, et al.
Publicado: (2021)

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
por: Liu, Frank Xiaoqing, et al.
Publicado: (2017)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Acute on Chronic Venous Thromboembolism on Therapeutic Anticoagulation
por: Bassi, Byron, et al.
Publicado: (2013)

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
por: Müller, Stephanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v32ctpoe5ihum89rns7g7buuvn